Actavis Inc (ACT) 214.67 $ACT
Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 1:00PM CDT
Actavis (ACT) second quarter results were boosted by the inclusion of products from the Warner Chilcott acquisition.
Ironwood Pharmaceuticals Narrows Q2 Loss, Revenues Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 10:00AM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share (excluding a one-time write-down of inventory) in the second quarter of 2014.
Actavis Guidance Disappoints; Akorn Beats And Raises
at Investor's Business Daily - Tue Aug 05, 9:29AM CDT
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis' earnings rose 70% over the...
Actavis reports 2Q profit
AP - Tue Aug 05, 7:44AM CDT
DUBLIN (AP) — Actavis PLC (ACT) on Tuesday reported a second-quarter profit after posting a loss in the same period a year ago. The company's results beat analysts' expectations.
Why Akorn (AKRX) Stock Is Advancing Today
at The Street - Tue Aug 05, 7:26AM CDT
Shares of Akorn (AKRX) are up after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm.
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42
PR Newswire - Tue Aug 05, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 34 percent to $2.67 billion for the second quarter ended June 30, 2014, compared to $1.99 billion in the second quarter 2013. On a non-GAAP basis, diluted earnings per share for the second quarter 2014 increased to $3.42, compared to $2.01 per diluted share in the second quarter 2013. GAAP earnings per diluted share for the second quarter 2014 were $0.28, compared to a GAAP loss per share of $4.27 in the prior year period.
Jim Cramer's Top Stock Picks: ACT AMZN CAH AAPL
at The Street - Tue Aug 05, 5:00AM CDT
Cramer says Actavis is inexpensive and has room to grow while Amazon can begin to rebound soon.
Jim Cramer's 'Mad Money' Recap: Watch Your Back
at The Street - Mon Aug 04, 6:59PM CDT
Forget what the pundits say, the real reason for the market's turmoil remains Russia, Cramer says.
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M
PR Newswire - Mon Aug 04, 7:50AM CDT
Today, Analysts Review released its research reports regarding Newfield Exploration Company (NYSE: NFX), YPF SA (NYSE: YPF), HCA Holdings Inc (NYSE: HCA), Actavis plc (NYSE: ACT) and 3M Company (NYSE: MMM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5394-100free.
Why Actavis (ACT) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 7:36AM CDT
Actavis has been witnessing a positive momentum in the earnings estimate front and possess a favorable Zacks Rank
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Many Leading Stocks Damaged As Market Tumbles Broadly
at Investor's Business Daily - Thu Jul 31, 1:51PM CDT
The stock market remained sharply lower in afternoon trading, a sell-off worsened by the many leading stocks coming under attack. The Nasdaq tumbled 1.6%, the S&P 500 1.4% and the Dow Jones industrial average 1.3%. The small-cap Russell 2000 skidded...
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 1:38PM CDT
The trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. Mutual funds holding these stocks in their portfolio should thus experience solid uplift in the near term.
Actavis May Give Buyers Another Chance
at Investor's Business Daily - Mon Jul 28, 5:03PM CDT
Drugmaker Actavis broke out of a cup-with-handle base June 18 but hasn't made much headway since then. It's slightly below a 216.80 buy point, struggling for support at its 50-day moving average. But it might be building a new handle and could make...
Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?
Brian Nichols, The Motley Fool - Motley Fool - Thu Jul 24, 7:54AM CDT
UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals , a company that UBS believes will benefit from continued patent...
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 1:00PM CDT
Actavis (ACT) second quarter results were boosted by the inclusion of products from the Warner Chilcott acquisition.
Ironwood Pharmaceuticals Narrows Q2 Loss, Revenues Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 10:00AM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share (excluding a one-time write-down of inventory) in the second quarter of 2014.
Actavis Guidance Disappoints; Akorn Beats And Raises
at Investor's Business Daily - Tue Aug 05, 9:29AM CDT
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis' earnings rose 70% over the...
Actavis reports 2Q profit
AP - Tue Aug 05, 7:44AM CDT
DUBLIN (AP) — Actavis PLC (ACT) on Tuesday reported a second-quarter profit after posting a loss in the same period a year ago. The company's results beat analysts' expectations.
Why Akorn (AKRX) Stock Is Advancing Today
at The Street - Tue Aug 05, 7:26AM CDT
Shares of Akorn (AKRX) are up after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm.
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42
PR Newswire - Tue Aug 05, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 34 percent to $2.67 billion for the second quarter ended June 30, 2014, compared to $1.99 billion in the second quarter 2013. On a non-GAAP basis, diluted earnings per share for the second quarter 2014 increased to $3.42, compared to $2.01 per diluted share in the second quarter 2013. GAAP earnings per diluted share for the second quarter 2014 were $0.28, compared to a GAAP loss per share of $4.27 in the prior year period.
Jim Cramer's Top Stock Picks: ACT AMZN CAH AAPL
at The Street - Tue Aug 05, 5:00AM CDT
Cramer says Actavis is inexpensive and has room to grow while Amazon can begin to rebound soon.
Jim Cramer's 'Mad Money' Recap: Watch Your Back
at The Street - Mon Aug 04, 6:59PM CDT
Forget what the pundits say, the real reason for the market's turmoil remains Russia, Cramer says.
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M
PR Newswire - Mon Aug 04, 7:50AM CDT
Today, Analysts Review released its research reports regarding Newfield Exploration Company (NYSE: NFX), YPF SA (NYSE: YPF), HCA Holdings Inc (NYSE: HCA), Actavis plc (NYSE: ACT) and 3M Company (NYSE: MMM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5394-100free.
Why Actavis (ACT) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 7:36AM CDT
Actavis has been witnessing a positive momentum in the earnings estimate front and possess a favorable Zacks Rank
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Many Leading Stocks Damaged As Market Tumbles Broadly
at Investor's Business Daily - Thu Jul 31, 1:51PM CDT
The stock market remained sharply lower in afternoon trading, a sell-off worsened by the many leading stocks coming under attack. The Nasdaq tumbled 1.6%, the S&P 500 1.4% and the Dow Jones industrial average 1.3%. The small-cap Russell 2000 skidded...
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 1:38PM CDT
The trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. Mutual funds holding these stocks in their portfolio should thus experience solid uplift in the near term.
Actavis May Give Buyers Another Chance
at Investor's Business Daily - Mon Jul 28, 5:03PM CDT
Drugmaker Actavis broke out of a cup-with-handle base June 18 but hasn't made much headway since then. It's slightly below a 216.80 buy point, struggling for support at its 50-day moving average. But it might be building a new handle and could make...
Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?
Brian Nichols, The Motley Fool - Motley Fool - Thu Jul 24, 7:54AM CDT
UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals , a company that UBS believes will benefit from continued patent...
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
